Laura E. Herring

Laura E. Herring

Auto-generated profile, based on publicly available information

Laura E. Herring

Michael Hooker Proteomics Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2017 in Nature Nanotechnology
Verified
Journal Article
Open access
PDF file
YMYuanzeng Min
Yuanzeng Min
KRKyle C. Roche
Kyle C. Roche
STShaomin Tian
Shaomin Tian
MEMichael J. Eblan
Michael J. Eblan
KMKaren P. McKinnon
Karen P. McKinnon
AWAndrew Wang
Andrew Wang
Nanoparticles can be utilized to capture tumour antigens and improve their presentation, which in turn improves the efficacy of cancer immunotherapy. Immunotherapy holds tremendous promise for improving cancer treatment1. To administer radiotherapy with immunotherapy has been shown to improve immune responses and can elicit the ‘abscopal effect’2. Unfortunately, response rates for this strategy remain low3. Herein we report an improved cancer immunotherapy approach that utilizes antigen-capturing nanoparticles (AC-NPs). We engineered several AC-NP formulations and demonstrated that the set of protein antigens captured by each AC-NP formulation is dependent on the NP surface properties. We showed that AC-NPs deliver tumour-specific proteins to antigen-presenting cells (APCs) and significantly improve the efficacy of αPD-1 (anti-programmed cell death 1) treatment using the B16F10 melanoma model, generating up to a 20% cure rate compared with 0% without AC-NPs. Mechanistic studies revealed that AC-NPs induced an expansion of CD8+ cytotoxic T cells and increased both CD4+T/Treg and CD8+T/Treg ratios (Treg, regulatory T cells). Our work presents a novel strategy to improve cancer immunotherapy with nanotechnology.

8 April 2024 in Nature
Verified
Journal Article
Open access
PDF file
UWUrszula N. Wasko
Urszula N. Wasko
JJJingjing Jiang
Jingjing Jiang
TDTanner C. Dalton
Tanner C. Dalton
ACAlvaro Curiel-Garcia
Alvaro Curiel-Garcia
AEA. Cole Edwards
A. Cole Edwards
KOKenneth P. Olive
Kenneth P. Olive
Broad-spectrum RAS inhibition has the potential to benefit roughly a quarter of human patients with cancer whose tumours are driven by RAS mutations1,2. RMC-7977 is a highly selective inhibitor of the active GTP-bound forms of KRAS, HRAS and NRAS, with affinity for both mutant and wild-type variants3. More than 90% of cases of human pancreatic ductal adenocarcinoma (PDAC) are driven by activating mutations in KRAS4. Here we assessed the therapeutic potential of RMC-7977 in a comprehensive range of PDAC models. We observed broad and pronounced anti-tumour activity across models following direct RAS inhibition at exposures that were well-tolerated in vivo. Pharmacological analyses revealed divergent responses to RMC-7977 in tumour versus normal tissues. Treated tumours exhibited waves of apoptosis along with sustained proliferative arrest, whereas normal tissues underwent only transient decreases in proliferation, with no evidence of apoptosis. In the autochthonous KPC mouse model, RMC-7977 treatment resulted in a profound extension of survival followed by on-treatment relapse. Analysis of relapsed tumours identified Myc copy number gain as a prevalent candidate resistance mechanism, which could be overcome by combinatorial TEAD inhibition in vitro. Together, these data establish a strong preclinical rationale for the use of broad-spectrum RAS-GTP inhibition in the setting of PDAC and identify a promising candidate combination therapeutic regimen to overcome monotherapy resistance.

25 April 2019 in ACS Chemical Biology
Verified
Journal Article
Open access
PGPaul R. Graves
Paul R. Graves
LALucas J. Aponte-Collazo
Lucas J. Aponte-Collazo
EFEmily M. J. Fennell
Emily M. J. Fennell
AGAdam C. Graves
Adam C. Graves
AHAndrew E. Hale
Andrew E. Hale
LGLee Graves
Lee Graves
ONC201 is a first-in-class imipridone molecule currently in clinical trials for the treatment of multiple cancers. Despite enormous clinical potential, the mechanism of action is controversial. To investigate the mechanism of ONC201 and identify compounds with improved potency, we tested a series of novel ONC201 analogs (TR compounds) for effects on cell viability and stress responses in breast and other cancer models. The TR compounds were found to be ~50-100 times more potent at inhibiting cell proliferation and inducing the integrated stress response (ISR) protein ATF4 than ONC201. Using immobilized TR compounds, we identified the human mitochondrial caseinolytic protease P (ClpP) as a specific binding protein by mass spectrometry. Affinity chromatography/drug competition assays showed that the TR compounds bound ClpP with ~10 fold higher affinity compared to ONC201. Importantly, we found that the peptidase activity of recombinant ClpP was strongly activated by ONC201 and the TR compounds in a dose- and time-dependent manner, with the TR compounds displaying a ~10-100 fold increase in potency over ONC201. Finally, siRNA knockdown of ClpP in SUM159 cells reduced the response to ONC201 and the TR compounds including induction of CHOP, loss of the mitochondrial proteins (TFAM, TUFM) and the cytostatic effects of these compounds. Thus, we report that ClpP directly binds ONC201 and the related TR compounds, and is an important biological target for this class of molecules. Moreover, these studies provide for the first time, a biochemical basis for the difference in efficacy between ONC201 and the TR compounds.

29 September 2021 in Science Translational Medicine
Verified
Journal Article
Open access
XYXufen Yu
Xufen Yu
DLDongxu Li
Dongxu Li
JKJithesh Kottur
Jithesh Kottur
YSYudao Shen
Yudao Shen
HKHuen Suk Kim
Huen Suk Kim
JJJian Jin
Jian Jin
WDR5-degrader-E3 ligase ternary complex structure–based design led to a highly effective WDR5 degrader with robust in vivo antitumor activities.

7 June 2024 in Science
Verified
Journal Article
Closed access
JKJeffrey A. Klomp
Jeffrey A. Klomp
JKJennifer E. Klomp
Jennifer E. Klomp
CSClint A. Stalnecker
Clint A. Stalnecker
KBKirsten L. Bryant
Kirsten L. Bryant
AEA. Cole Edwards
A. Cole Edwards
CDChanning Der
Channing Der
How theKRASoncogene drives cancer growth remains poorly understood. Therefore, we established a systemwide portrait of KRAS- and extracellular signal–regulated kinase (ERK)–dependent gene transcription in KRAS-mutant cancer to delineate the molecular mechanisms of growth and of inhibitor resistance. Unexpectedly, our KRAS-dependent gene signature diverges substantially from the frequently cited Hallmark KRAS signaling gene signature, is driven predominantly through the ERK mitogen-activated protein kinase (MAPK) cascade, and accurately reflects KRAS- and ERK-regulated gene transcription in KRAS-mutant cancer patients. Integration with our ERK-regulated phospho- and total proteome highlights ERK deregulation of the anaphase promoting complex/cyclosome (APC/C) and other components of the cell cycle machinery as key processes that drive pancreatic ductal adenocarcinoma (PDAC) growth. Our findings elucidate mechanistically the critical role of ERK in driving KRAS-mutant tumor growth and in resistance to KRAS-ERK MAPK targeted therapies.

9 March 2017 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
XLXinghui Li
Xinghui Li
ZZZhibin Zhang
Zhibin Zhang
LLLupeng Li
Lupeng Li
WGWei Gong
Wei Gong
ALAudrey J. Lazenby
Audrey J. Lazenby
HWHaitao Wen
Haitao Wen
Signal transducer and activator of transcription 3 (STAT3) is a key mediator of intestinal inflammation and tumorigenesis. However, the molecular mechanism that modulates STAT3 phosphorylation and activation is not fully understood. Here, we demonstrate that modification of STAT3 with O-linked β-N-acetylglucosamine (O-GlcNAc) on threonine 717 (T717) negatively regulates its phosphorylation and targets gene expression in macrophages. We further found that cullin 3 (CUL3), a cullin family E3 ubiquitin ligase, down-regulates the expression of the O-GlcNAc transferase (OGT) and inhibits STAT3 O-GlcNAcylation. The inhibitory effect of CUL3 on OGT expression is dependent on nuclear factor E2–related factor-2 (Nrf2), which binds to the Ogt promoter region and increases gene transcription. Myeloid deletion of Cul3 led to defective STAT3 phosphorylation in colon macrophages, which was accompanied by exacerbated colonic inflammation and inflammation-driven tumorigenesis. Thus, this study identifies a new form of posttranslational modification of STAT3, modulating its phosphorylation, and suggests the importance of immunometabolism on colonic inflammation and tumorigenesis.